The Importance of Donor Cell Selection in ALS Treatment

In the context of ALS treatment, donor cell selection plays an important role in ensuring patients receive optimal treatment that treats their disease and improves their quality of life.
Keep reading to learn more about donor cell selection, as we break down the different types of donor cells, the role of donor cell selection in ALS treatment and the factors in selecting donor cells for ALS treatment.

Understanding Different Types of Donor Cells

Stem cell research has identified various types of stem cells suitable for stem cell therapy.

Overview of Stem Cell Sources

One of the most common stem cell sources is blood marrow. Blood marrow stem cells were one of the first types of stem cells discovered and were first used in 1959 as a hematopoietic stem cell transplant (HSCT).
MSCs for ALS stem cell therapy can also come from bone marrow, fat tissue or gum tissue, or the umbilical cord or placenta of a newborn. Some treatment centers, such as Swiss Medica, also stem cell exosomes as part of their stem cell therapy. 
Stem cells can be obtained from human embryos, but this is a very controversial method, as it requires the destruction of a human embryo. Side effects commonly associated with stem therapy have been seen with the use of embryonic stem cells, not MSCs. MSCs are a safe and ethical alternative to embryonic stem cells.

Criteria for Donor Cell Selection

During the donor cell selection process, certain criteria must be considered, such as:

• Donor and recipient age
• Health of donor and recipient

In addition, the treatment can use the stem cells of the recipient as long as they’re healthy enough and have no contraindications to stem cell extraction. 

The Role of Mesenchymal Stromal Cells (MSCs) in ALS

Due to their immuno-regulatory and anti-inflammatory properties, as well as their ability to differentiate, mesenchymal stromal cells (MSCs) hold great promise in treating ALS.

Advantages of MSCs for ALS Treatment

MSCs can be particularly effective in treating ALS. Stem cell treatment can prevent further loss of neurons and help promote the growth of new ones, slowing the progression of the disease and improving symptoms such as loss of motor control, stiffness and tremors.
These positive effects are also backed by research. In several animal studies, MSCs delayed the progression of ALS and restored at least some motor functions. In a mouse model studying the effect of MSCs on ALS, MSCs reduced neuroinflammation, improved motor performance and increased lifespan. 
ALS treatment using MCSs is a noninvasive treatment with no serious side effects for ALS patients. In addition, treatment centers like Swiss Medica use MSC exosome therapy to reduce immune responses in ALS patients.

Optimizing Donor Cell Selection for Effective ALS Treatment

Factors Influencing Donor Cell Selection

MSCs can be obtained from blood marrow, umbilical cords, placenta or fat tissue. Effective ALS treatment must use donor cells with as few side effects as possible. Therefore, embryonic stem cells aren’t used for ALS treatment, as these stem cells can produce adverse effects and the source of these cells poses ethical questions.
Donor cells for ALS can be obtained from blood marrow, fat tissue, an umbilical cord or a placenta. The donor must be healthy and the quality and quantity of the stem cells must be sufficient. Stem cells from umbilical cords have been shown to have more immunomodulatory benefits, which could help in treating ALS.
Many people assume donor cell selection requires donor-recipient compatibility, but this is not the case with MSCs, as it’s very unlikely a recipient’s immune system will reject them. 

Future Directions in Donor Cell Research for ALS

As stem cell research continues to develop, we’ll likely see more effective stem cell treatments. For example, there is promising research into neural stem cells. Neural stem cells can differentiate into various brain cells, which could be especially beneficial for the degeneration of cells in the brain and spinal cord, as with ALS.

In conclusion

Mesenchymal stromal cells (MSCs) are the most commonly used stem cells for  ALS treatment, due to the ethical sourcing of these stem cells and the lack of serious side effects. MSCs can be sourced from bone marrow and fat tissue or the umbilical cord or placenta of a newborn.
There are many advantages of MSC Treatment for ALS, however, to ensure that stem cells are of high quality, the donor’s health, age and quality of stem cells must be taken into consideration.